Evidence map›Paper›PMID 42694072›Full record

ArticleFrontiers in oncology2026

Serum DIP2C protein concentration in human colorectal cancer among Yemeni patients.

Gamal Othman Dabwan

Abstract read
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Gamal Othman DabwanDepartment of Biochemistry and Molecular Biology, Faculty of Medicine and Health Sciences, Sana'a University, Sana'a, Yemen.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Colorectal cancer (CRC) forms a serious health challenge in developed countries. In Yemen, khat ( Objective: This study aimed to investigate the serum Methods: In this study, 214 Yemeni adults aged 20-90 years were enrolled, including 73 CRC patients (25 with MetS and 48 without MetS) and 141 non-cancerous individuals (70 non-CRC, non-MetS subjects served as controls, and 71 non-CRC, MetS subjects). Results: Serum Conclusion: Yemeni patients with colorectal cancer have noticeably low serum

Indexed as

alternative splicingCRCDIP2Ckhatlifestylessmokingtranscriptiontranslation

Identifiers

PMID42694072
PMCPMC13538005

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.